Ovid Therapeutics (OVID) Q2 2026 earnings summary

Executive summary

• Focused on developing small molecule medicines for brain disorders, with a pipeline targeting drug-resistant seizures and neuropsychiatric conditions, including OV329 and OV4071 in clinical trials and additional candidates in preclinical development.

• Advanced OV4071, the first oral direct KCC2 activator, in an ongoing Phase 1 study with plans for Phase 2 in acute schizophrenia in 2027.

• Initiated Phase 2 proof-of-concept and photosensitivity studies for OV329, a next-generation GABA-AT inhibitor, targeting multiple seizure disorders.

• Monetized global rights to soticlestat via a new portfolio company, securing equity, milestone payments, and royalties.

• Strengthened leadership with key executive appointments and board expansion.

Financial highlights

• Cash, cash equivalents, and marketable securities totaled $169.8 million as of June 30, 2026, providing runway into 2029.

• Net loss of $32.0 million for the six months ended June 30, 2026, compared to $14.9 million in the prior year period.

• Revenue for the six months ended June 30, 2026 was $0.7 million, down from $6.4 million year-over-year, primarily from licensing agreements.

• Research and development expenses increased to $21.1 million for the six months ended June 30, 2026, and were $10.0 million for Q2 2026, up from $6.5 million in Q2 2025.

• General and administrative expenses rose to $13.1 million for the six months ended June 30, 2026, and $6.5 million for Q2 2026, mainly due to higher legal and professional fees.

Outlook and guidance

• Management expects to incur significant operating losses for the foreseeable future and anticipates increased expenses as clinical programs advance.

• Financial runway expected to last into 2029, supporting ongoing and planned clinical programs.

• Current cash resources are expected to fund operations for at least the next 12 months.

• Additional capital may be required through equity, debt, or strategic transactions.

• Anticipates completion of OV329 Phase 2 FOS study in H2 2027 and initiation of additional studies in TSC and IS in late 2026 and 2027.